RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radio-pharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radio-pharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radio-labeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.
RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.
Innovative targeted radiopharmaceuticals, Biotechnology, Generator-produced radiopharmaceuticals based on Gallium-68, and Development of a new diagnostic and therapeutic radiolabeled agents
We are thrilled to announce a groundbreaking licensing agreement with Sanofi and Orano Med to advance next generation radioligand medicine for rare cancers. This collaboration marks a significant step forward in our mission to develop innovative treatments for patients in need. Orano MedSanofiEbrahim Delpassand, M.D.Izabela Tworowska
🎇Happy Fourth of July! our office will be closed on July 4th as we celebrate the 4th of July, we honor the birth of the United States of America—the day when the Declaration of Independence was adopted in 1776
Let us remember the sacrifices of those who fought for our liberty and reflect on the principles that unite us. Our offices will be closed today, but we’ll be back to serve you tomorrow, July 5th.
Enjoy the fireworks, spend time with loved ones, and embrace the spirit of unity that defines our nation.
#radiomedix#4thjuly#radiopharmaceuticals#Oranomed#radiotherapy#nucmed#nuclearmedicine🧪